Charles River Laboratories International, Inc. (crl)
CRL — Company Overview
Charles River Laboratories International, Inc. (CRL) is a large-cap company in the Healthcare sector, operating in Diagnostics & Research.
| Ticker | CRL |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Exchange | NYQ |
| Market cap | $13.36B |
| Last price | $277.33 |
| Size category | Large Cap |
CRL — Business Description
Charles River Laboratories International, Inc. (CRL) operates in Diagnostics & Research within the broader Healthcare market. Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offe…
Official website: https://www.criver.com.
CRL — Investment Thesis
The investment thesis for Charles River Laboratories International, Inc. (CRL) rests on how Healthcare dynamics, profitability, and valuation interact at today's price.
- Revenue is contracting at roughly -2.7% year-over-year (public data).
- Equity market capitalization is approximately $13.36B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
CRL — Financial Health
Financial health for Charles River Laboratories International, Inc. (CRL) is summarized from publicly reported profitability, leverage, and cash-flow metrics.
Negative profit margin (-6.0%) signals near-term profitability pressure. Positive free cash flow of $468.86M supports balance-sheet flexibility. Debt-to-equity of 105.05 warrants monitoring in a higher-rate environment.
| Forward P/E | 21.82× |
| Price / Sales | 3.31× |
| Price / Book | 4.66× |
| Gross margin | 34.6% |
| Operating margin | 15.1% |
| Profit margin | -6.0% |
| Return on equity | -7.5% |
| Debt / Equity | 105.05 |
| Free cash flow | $468.86M |
CRL — Growth Outlook
Growth outlook for Charles River Laboratories International, Inc. (CRL) depends on demand trends in Diagnostics & Research and the company's ability to convert revenue into sustainable earnings.
- Revenue decline of -2.7% highlights near-term demand headwinds.
- Price is 8.6% below the 52-week high.
CRL — Competitive Position
Charles River Laboratories International, Inc. (CRL) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Diagnostics & Research.
- Market capitalization of $13.36B places CRL among large-cap peers.
- Gross margin of 34.6% should be benchmarked against direct competitors.
CRL — Strengths
Strengths for Charles River Laboratories International, Inc. (CRL) inferred from public financial metrics:
- Positive free cash flow ($468.86M).
- Large Cap scale ($13.36B) may provide distribution and funding advantages.
CRL — Weaknesses
Weaknesses and pressure points for Charles River Laboratories International, Inc. (CRL) based on available data:
- Revenue contraction of -2.7% year-over-year.
- Thin profit margin (-6.0%).
- High beta (1.41) amplifies market swings.
CRL — Opportunities
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
CRL — Risks
- Beta of 1.41 implies above-market volatility.
- Negative revenue growth may signal share loss or cyclical pressure.
- Thin margins leave less room for operational missteps.
CRL — Summary
Charles River Laboratories International, Inc. (CRL) is a large-cap Healthcare company focused on Diagnostics & Research, listed on NYQ. Last price $277.33 with market cap $13.36B. Revenue declined -2.7% year-over-year per public data. Notable strengths include positive free cash flow ($468.86m). Key watch items include revenue contraction of -2.7% year-over-year. Public estimates and earnings snapshots for Charles River Laboratories International, Inc. are on this site; ownership, live news, and deeper models remain in Vest Terminal.
Start Free — open CRL in Vest Terminal
Access live data, filings, ownership, and analysis for Charles River Laboratories International, Inc..
Charles River Laboratories International, Inc. FAQ
What does Charles River Laboratories International, Inc. (CRL) do?
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and pur…
What is CRL's P/E ratio?
Charles River Laboratories International, Inc. has a trailing P/E of N/A× based on publicly available market data.
Does CRL pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is CRL in?
Charles River Laboratories International, Inc. is classified in Healthcare (Diagnostics & Research) on NYQ.
What is CRL's market capitalization?
Approximate market cap: $13.36B.
What are the main risks for CRL?
Key risks include above-average volatility (beta 1.41), negative revenue growth, among factors on this page.
What are the strengths of CRL?
Potential positives include positive free cash flow ($468.86m), large cap scale ($13.36b) may provide distribution and funding advantages.
Where can I get analyst estimates for CRL?
Public analyst price targets and consensus for Charles River Laboratories International, Inc. are on the free /stocks/crl/estimates page. Deeper estimate history and models are available in Vest Terminal.